{"id":"W4206224214","doi":"10.1016/j.ajo.2022.01.004","title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","year":2022,"lang":"en","type":"article","venue":"American Journal of Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa","funders":"Allergan; Bayer Fund; AbbVie; Roche; Novartis Pharmaceuticals Corporation; Novartis","keywords":"Diabetic macular edema; Edema; Kestrel; Diabetic retinopathy; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006815637,0.0001766104,0.001398452,0.0001773101,0.00008757493,0.00000766186,0.0001301011,0.00002651508,0.0003017883],"category_scores_gemma":[0.000666571,0.000140757,0.0004357501,0.0001722145,0.0003013447,0.00004263343,0.0000657351,0.0001833752,9.572541e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006526133,"about_ca_system_score_gemma":0.0002035759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002924761,"about_ca_topic_score_gemma":1.38987e-7,"domain_scores_codex":[0.9975964,0.0004385802,0.001169267,0.0002460621,0.0002988758,0.0002508537],"domain_scores_gemma":[0.9967416,0.001000262,0.001632671,0.0002174459,0.0001438452,0.0002641805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4672025,0.01826738,0.1395405,0.0002460785,0.01289626,0.06098593,0.00344322,0.0005175556,0.03765671,0.0002113792,0.002786473,0.256246],"study_design_scores_gemma":[0.3626706,0.2630602,0.2154627,0.0004943205,0.01110466,0.125254,0.008530058,0.001178895,0.003679305,0.004732659,0.002852879,0.0009797304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957107,0.001868858,0.00005156955,0.0007279009,0.0002098286,0.0003736758,0.0008541615,0.000003845494,0.0001994342],"genre_scores_gemma":[0.9974334,0.00006225159,0.001965242,0.00007609677,0.0001913138,0.00002122322,0.0001111728,0.0000245798,0.0001147739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2552663,"threshold_uncertainty_score":0.5739905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04505861785045452,"score_gpt":0.3744115443462498,"score_spread":0.3293529264957953,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}